TG Therapeutics | TGTX - Net Income


TG Therapeutics reported $7.78M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
AbbVie USD 3.61B 2.92B Jun/2026
Alaunos Therapeutics USD -1.01M 153K Mar/2026
Amgen USD 2.38B 556M Jun/2026
Ardelyx USD -37.6M 37.2M Mar/2026
Arrowhead Research USD -132.73M 163.54M Mar/2026
Bayer EUR 2.76B 6.52B Mar/2026
Biogen USD 97.5M 222M Jun/2026
Corcept Therapeutics USD 42.14M 73.9M Jun/2026
Curis USD -24.2M 43.56M Mar/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
J&J USD 5.53B 299M Jun/2026
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026
Novartis USD 3.26B 108M Jun/2026
Novavax USD 17.53M 219.91M Dec/2025
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
TG Therapeutics USD 7.78M 12M Jun/2026
Verastem USD -36.59M 3.68M Mar/2026
Vertex Pharmaceuticals USD 1.1B 68.4M Jun/2026